SignalXSignalX

EW Edwards Lifesciences

FY2024 10-K
Filed: Feb 28, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR
Edwards Lifesciences Overview

Edwards Lifesciences (EW) filed its fiscal year 2024 10-K annual report with the SEC on Feb 28, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Business Overview

  • • Core business model: Development, manufacturing, and marketing of structural heart therapies and medical technologies globally
  • • New emphasis on divestiture of Critical Care product group completed Sept 2024 to refine portfolio focus
+3 more insights

Management Discussion & Analysis

  • • Revenue $5.44B, up $429.5M (8.6%) YoY in 2024, driven by TAVR and TMTT growth
  • • Gross profit margin declined due to foreign currency impact; exact margin % figures not disclosed
+3 more insights

Risk Factors

  • • No specific, timely regulatory or legal risk identified in the text
  • • No geopolitical or macroeconomic threat with concrete exposure details mentioned
+3 more insights

Financial Summary
XBRL

Revenue

$5.4B

Net Income

$4.2B

Gross Margin

79.5%

Operating Margin

25.3%

Net Margin

76.7%

ROE

41.8%

Total Assets

$13.1B

EPS (Diluted)

$6.97

Operating Cash Flow

$542M

Source: XBRL data from Edwards Lifesciences FY2024 10-K filing on SEC EDGAR. All figures in USD.

Other Edwards Lifesciences Annual Reports

FY2025 10-K

Get deeper insights on Edwards Lifesciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available